|
1
|
Liu X, Chen D, Liu J, Chu Z and Liu D:
Blocking modification of eukaryotic initiation 5A2 antagonizes
cervical carcinoma via inhibition of RhoA/Rock signal transduction
pathway. Technol Cancer Res Treat. 16:630–638. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thomakos N, Trachana SP,
Davidovic-Grigoraki M and Rodolakis A: Less radical surgery for
early-stage cervical cancer: To what extent do we justify it? Our
belief. Taiwan J Obstet Gynecol. 55:495–498. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
National Cancer Institute: SEER Data:
Surveillance, epidemiology and end results program. http://seer.cancer.gov/statfacts/html/cervix.html16–January.
2017
|
|
4
|
Mallmann P and Mallmann C: Neoadjuvant and
adjuvant chemotherapy of cervical cancer. Oncol Res Treat.
39:522–524. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brucker SY and Ulrich UA: Surgical
treatment of early-stage cervical cancer. Oncol Res Treat.
39:508–514. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li H, Wu X and Cheng X: Advances in
diagnosis and treatment of metastatic cervical cancer. J Gynecol
Oncol. 27:e432016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zong M, Fan DD, Lin S, Song YP, Wang ZY,
Ma XL, Qiu WH, Bai YH, Li L and Li S: Anti-cancer activity and
potential mechanism of a novel aspirin derivative. Eur J Pharmacol.
791:137–146. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Montrose DC, Zhou XK, McNally EM, Sue E,
Yantiss RK, Gross SS, Leve ND, Karoly ED, Suen CS, Ling L, et al:
Celecoxib alters the intestinal microbiota and metabolome in
association with reducing polyp burden. Cancer Prev Res (Phila).
9:721–731. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jawanjal P, Salhan S, Dhawan I, Das N,
Aggarwal R, Tripathi R and Rath G: Augmented activity of
cyclooxygenase-2 in tissue and serum of patients with cervical
cancer. J Clin Lab Anal. 30:1198–1207. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Setiawati A and Setiawati A: Celecoxib, a
COX-2 selective inhibitor, induces cell cycle arrest at the G2/M
phase in HeLa cervical cancer cells. Asian Pac J Cancer Prev.
17:1655–1660. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang Z: A review of progress in clinical
photodynamic therapy. Technol Cancer Res Treat. 4:283–293. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dougherty TJ, Henderson BW, Schwartz S,
Winkelman JW and Lipson RL: Historical Perspective in Photodynamic
Therapy. Henderson BW and Dougherty TJ: Maurice Dekker; New York,
NY: pp. 1–18. 1992
|
|
13
|
Garg T, Jain NK, Rath G and Goyal AK:
Nanotechnology-based photodynamic therapy: Concepts, advances and
perspectives. Crit Rev Ther Drug Carrier Syst. 32:389–439. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Almeida RD, Manadas BJ, Carvalho AP and
Duarte CB: Intracellular signaling mechanisms in photodynamic
therapy. Biochim Biothys Acta. 1704:59–86. 2004.
|
|
15
|
Zhou Z, Yang H and Zhang Z: Role of
calcium in phototoxicity of 2-butylamino-2-demethoxy-hypocrellin A
to human gastric cancer MGC-803 cells. Biochim Biophys Acta.
1593:191–200. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stern PL, van der Burg SH, Hampson IN,
Broker TR, Fiander A, Lacey CJ, Kitchener HC and Einstein MH:
Therapy of human papillomavirus-related disease. Vaccine. 30 Suppl
5:F71–F82. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Olivo M, Bhuvaneswari R, Lucky SS,
Dendukuri N and Thong Soo-Ping P: Targeted therapy of cancer using
photodynamic therapy in combination with multi-faceted anti-tumor
modalities. Pharmaceuticals (Basel). 3:1507–1529. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gariepy H, Zhao J and Levy D: Differential
contribution of COX-1 and COX-2 derived prostanoids to cortical
spreading depression-Evoked cerebral oligemia. J Cereb Blood Flow
Metab. 37:1060–1068. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Son DJ, Akiba S, Hong JT, Yun YP, Hwang
SY, Park YH and Lee SE: Piperine inhibits the activities of
platelet cytosolic phospholipase A2 and thromboxane A2 synthase
without affecting cyclooxygenase-1 activity: Different mechanisms
of action are involved in the inhibition of platelet aggregation
and macrophage inflammatory response. Nutrients. 6:3336–3352. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Akasaka H and Ruan KH: Identification of
the two-phase mechanism of arachidonic acid regulating inflammatory
prostaglandin E2 biosynthesis by targeting COX-2 and mPGES-1. Arch
Biochem Biophys. 603:29–37. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Boutaud O, Sosa IR, Amin T, Oram D, Adler
D, Hwang HS, Crews BC, Milne GL, Harris BK, Hoeksema M, et al:
Inhibition of the biosynthesis of prostaglandin E2 by low dose
aspirin: Implications for adenocarcinoma metastasis. Cancer Prev
Res (Phila). 9:855–865. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shigemasa K, Tian X, Gu L, Shiroyama Y,
Nagai N and Ohama K: Expression of cyclooxygenase-2 and its
relationship to p53 accumulation in ovarian adenocarcinomas. Int J
Oncol. 22:99–105. 2003.PubMed/NCBI
|
|
23
|
Gawthorpe S, Brown JE, Arif M, Nightingale
P, Nevill A and Carmichael AR: Heparanase and COX-2 expression as
predictors of lymph node metastasis in large, high-grade breast
tumors. Anticancer Res. 34:2797–2800. 2014.PubMed/NCBI
|
|
24
|
Chen YJ, Wang LS, Wang PH, Lai CR, Yen MS,
Ng HT and Yuan CC: High cyclooxygenase-2 expression in cervical
adenocarcinomas. Gynecol Oncol. 88:379–385. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou WQ, Sheng QY, Sheng YH, Hou WJ, Xu
GX, Wu YM and Lu H: Expressions of survivin, P16(INK4a), COX-2 and
Ki-67 in cervical cancer progression reveal the potential clinical
application. Eur J Gynaecol Oncol. 36:62–68. 2015.PubMed/NCBI
|
|
26
|
Liu H, Xiao J, Yang Y, Liu Y, Ma R, Li Y,
Deng F and Zhang Y: COX-2 expression is correlated with VEGF-C,
lymphangiogenesis and lymph node metastasis in human cervical
cancer. Microvasc Res. 82:131–140. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xia S, Zhao Y, Yu S and Zhang M: Activated
PI3K/Akt/COX-2 pathway induces resistance to radiation in human
cervical cancer HeLa cells. Cancer Biother Radiopharm. 25:317–323.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gaffney DK, Holden J, Davis M, Zempolich
K, Murphy KJ and Dodson M: Elevated cyclooxygenase-2 expression
correlates with diminished survival in carcinoma of the cervix
treated with radiotherapy. Int J Radiat Oncol Biol Phys.
49:1213–1217. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sakonlaya D, Tapanadechopone P, Poomkokruk
A and Charoenvilaisiri S: Do NSAIDs inhibit growth of precancerous
cervical cells in vitro? J Med Assoc Thai. 95 Suppl 1:S65–S73.
2012.PubMed/NCBI
|
|
30
|
Wang AH, Tian XY, Yu JJ, Mi JQ, Liu H and
Wang RF: Celecoxib radiosensitizes the human cervical cancer HeLa
cell line via a mechanism dependent on reduced cyclo-oxygenase-2
and vascular endothelial growth factor C expression. J Int Med Res.
40:56–66. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sadeghi-Aliabadi H, Aliasgharluo M,
Fattahi A, Mirian M and Ghannadian M: In vitro cytotoxic evaluation
of some synthesized COX-2 inhibitor derivatives against a panel of
human cancer cell lines. Res Pharm Sci. 8:298–303. 2013.PubMed/NCBI
|
|
32
|
Colussi VC, Feyes DK, Mulvihill JW, Li YS,
Kenney ME, Elmets CA, Oleinick NL and Mukhtar H: Phthalocyanine 4
(PC4) photodynamic therapy of human OVCAR-3 tumor xenografts.
Photochem Photobiol. 69:236–241. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guyon L, Farine MO, Lesage JC, Gevaert AM,
Simonin S, Schmitt C, Collinet P and Mordon S: Photodynamic therapy
of ovarian cancer peritoneal metastasis with hexaminolevulinate: A
toxicity study. Photodiagnosis Photodyn Ther. 11:265–274. 2014.
View Article : Google Scholar : PubMed/NCBI
|
